A proven, comfortable interface ready for your patient and their wound, regardless of what stands in the way.

Unique TLC technology
promotes healing

The TLC (Technology Lipido-Colloid) matrix is a flexible dressing comprising polyester mesh impregnated with hydrocolloid and petroleum jelly particles that allows a gel to form when it comes in contact with the wound exudate, forming a moist environment within the wound, thereby promoting healing.

Which TLC dressing is right for my patient’s wound?

Do you need to defend what does belong or attack what doesn’t belong?

Moisture Management

The TLC dressings have the ability to adapt to any changes in moisture level between your dressing changes.

If the moisture level is low, the interface can retain fluid. If the moisture is too high, the TLC dressings allow the excess to pass through the dressing, thus repelling the excess fluid.

Plus sign.
Icon with the text: PASS ON EXCESSIVE FLUID.
The only hydrophilic interface on the market providing you the best of both worlds.

Atraumatic and Pain-free Removal

Due to its unique design that retains its integrity over time, the TLC matrix allows for a pain-free and atraumatic removal process, giving your patient the best outcomes to facilitate wound progress.

Character of lesions following dressing removal1

Fibrous green matrix with the following text overlay: TLC Restoring matrix.

Significant absence of lesions after removal, up to 8 days

Fibrous green matrix with eye-shaped black mass with the following text overlay: Traditional gauze.

Eradication of fibroblasts and of the extracellular matrix after removal

Sacrum bandage shaped pink icon.

Clinical consequences at removal

Icon with the text: REPEL EXCESSIVE FLUID.

With TLC Restoring Matrix (UrgoTul)

Icon with the text: REPEL EXCESSIVE FLUID.

Eradication of fibroblasts with traditional gauze after removal

UrgoTul was associated with no or less pain at dressing change2

Bar graph labled 'Acute wounds'. Traditional dressings show 100% of patients with pain, while UrgoTul shows only 5% of patients with pain.
Bar graph labled 'Chronic wounds'. Traditional dressings show 100% of patients with pain, while UrgoTul shows only 12% of patients with pain.

Acceptability of TLC dressing (UrgoTul)3

Bar graph with y-axis labelled 'Patient (%). Reference 0. The following bars and data are shown: Very easy application (100%), Very easy removal (100%), No adherence to the wound (100%), No bleeding on removal (100%), No pain on removal (100%), No or minimal odor (86%), No maceration (96%).

UrgoTul range is clinically proven in more than 11,600 patients4

1-year-old child presenting with a partial-thickness burn on the inside of the arm; after 15 days of treatment with UrgoTul, the wound has fully epithelialized5

1-year-old child with wound pre-treatment.
1-year-old child with wound after 15 days of treatment with UrgoTul.

13-month-old presenting with a traumatic wound on the forehead following a traffic accident; after 7 days the wound was healed5

13-month-old child with wound pre-treatment.
13-month-old child with wound 7 days after would was healed.


UrgoTul range is clinically proven to provide a nuturing environment for healing and harm-free care for your patient

Cellular morphology - confocal microscopy (72 h)1,6,7

Urgotal in control.
Urgotal in cell division.
Urgotal in petroleum water interface.
Urgotal dressing impregnated with petroleum.
Urgotal dressing impregnated with paraffin.
Urgotal dressing impregnated with silicone.

Assessment of fibroblast proliferation

Line graph of cellular morphology with Urgotul. Urgotal improves by up to 70 percent fibroblasts proliferation.
Legend for the line graph.

Effects on the synthesis of hyaluronic acid8

Bar graph of Urgotul effects on synthesis. It improves by 53 percent.

Effects on the production/release of soluble (pro)-collagen I8

Bar graph of Urgotul effects on production/release. It improves by 80 percent.


UrgoTul Ag is clinically proven to facilitate wound progress, with reduced signs of local infection over neutral dressings8


  • Randomized controlled trial, multicentered
  • 102 Patients RCT, 2 groups (sequential group): UrgoTul Ag/UrgoTul; neutral group: UrgoTul)
  • Leg ulcers presenting signs suggesting heavy bacteria load

A significantly lower clinical score with the sequential TLC-Ag group

Clinical scores of Urgotul after 4 weeks and 8 weeks.

A very good safety profile of the TLC-Ag dressing

The TLC-Ag dressing did not induce any increase in blood silver levels in the patients checked

47.9% wound surface reduction with the sequential TLC-Ag group (p=0.036)

Graph of wound surface area reduction cause by Urgotul Ag.

Clinical Support

For more in-depth information about the UrgoTul and UrgoTul Ag difference, please see the following resources and product brochures.

1. Study report No. S/2003-007/BIOalternatives 2. Meaume S, et al. The importance of pain reduction through dressing selection in routine wound management: the MAPP study. J Wound Care. 2004;13(10):409-13. 3. Benbow M., losson, G. A clinical evaluation of UrgoTul to treat acute and chronic wounds. Br J Nurs. 2004;13(2):105-9. 4. White, R., Cowan, T., Glover, D. Supporting evidence-based practice: review of TLC healing matrix (2nd edition). MA Healthcare Ltd, London 2015. 5. Le Touze A, et al. Interest of a new dressing (UrgoTul) in the management of wounds in a pediatric setting: results from a european clinical study. Poster, CPC 2005, Paris. 6. Bernard FX et al. Stimulation of the proliferation of human dermal fibroblasts in vitro by a lipidocolloid dressing. J Wound Care. 2005;14(5):215-20. 7. M. Le Berre, Y. Lurton et al., Coated dressings: gauzes/contact layers. Oral communication, CPC 2005, Paris. 8. Bernard FX et al. Effects of a lipidcolloid dressing on the production of the extracellular matrix. Journal des Plaies et Cicatrisations, 2007 (study conducted on UrgoTul).